Marcus

Marcus is an active 35-year-old and has been diagnosed with Autosomal Dominant Polycystic Kidney Disease (ADPKD). He has high blood pressure, but it is well-controlled with medication. PKD has affected Marcus' daily life as he has suffered from lower back and side pain for the past 10 years. Marcus has also had a cyst infection and a few episodes of blood in the urine. Marcus does not have a family history of kidney disease and he is very anxious about what his future holds.

Let’s take a closer look at some tests Marcus' kidney doctor has ordered to better understand how quickly Marcus might progress to kidney failure1,2.

  • Age35
  • Height5'11"
  • Weight171 lbs
  • SexM
  • Race (AA/O)AA

Lab Tests

Standard Range
Serum Creatinine

(mg/dL)

1.150.50 - 1.20
eGFR

(mL/min/1.73m²)

9760
1
Blood Pressure

(mmHg)

130/80

(High, Controlled with Medication)

< 120/80
Blood in Urine

Yes
2
Pain

Yes
3
Family History

No

Imaging Tests

Standard Range
MRI Ordered?

Yes
Kidney Size

(mL/m)

1343150-250
  • ADPKD Imaging Classification

    ESTIMATED AGE AT KIDNEY FAILURE51

    MRI/CT SCANSCoronal ViewTransverse View

Disease Progression3-5

Kidney function (eGFR): 97.0 mL/min/1.73m2
CKD 1CKD 2CKD 3CKD 4CKD 5/ESRDYears20253035404550mL/min/1.73m²050100
Kidney Size (height adjusted Total Kidney Volume) : 1343.0 mL/m
Normal htTKV range: 150-250Years20253035404550mL/m05001000150020002500300035004000
20
25
30
35
40
45
50

Years

Click on the flags below to see the testing used to confirm risk of rapid disease progression as well as Marcus’ individual risk

ADPKD=autosomal dominant polycystic kidney disease; PKD=polycystic kidney disease; TKV=total kidney volume; AA=African American; O=other; eGFR=estimated glomerular filtration rate; ESKD=end stage kidney disease; htTKV=height-adjusted TKV; MRI=magnetic resonance imaging; CT=computed tomography; CKD=chronic kidney disease.
References:
  1. Schrier RW, et al. Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol. 2014;25:2399-2418.

  2. Gansevoort RT, et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant. 2016;31(3):337-48.

  3. Delgado, C. et al. (2022) “A unifying approach for GFR estimation: Recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease,” American Journal of Kidney Diseases, 79(2). Available at: https://doi.org/10.1053/j.ajkd.2021.08.003.

  4. Irazabal MV, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26:160-172.

  5. Imaging classification of ADPKD: a simple model for selecting patients for clinical trials. http://www.mayo.edu/research/documents/pkd-center-adpkd-classification/doc-20094754. Accessed 1/11/2023.

The information provided through ADPKDsim website is intended for your educational benefit only. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Users seeking medical advice should consult with a health care professional.